Photo: Alethio Therapeutics
A British biotech company has raised $90 million to move an experimental blood-cancer treatment toward human testing. For patients, it is funding for research, not a new medicine they can receive today.
Oxford-based Alethio Therapeutics announced the Series A financing November 5. Sofinnova Partners and RA Capital co-led the round alongside founding investor Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford.
The company said the money will fund Phase 1/2a studies of its lead drug candidate, ATX-011, in essential thrombocythemia, a chronic blood cancer in which the body makes too many platelets. Platelets help blood clot; the disease can raise the risk of dangerous clots and bleeding.
What the money is meant to buy
Alethio says the financing should carry ATX-011 through those early studies to readiness for Phase 3 development. It also plans to move other programs toward applications needed to begin clinical testing.
That is the company’s development plan, not a promise that larger trials will begin or succeed. The announcement says ATX-011 is still in studies needed before an investigational new drug application and is moving toward clinical development. It does not report results from patients treated with the drug or announce a trial opening date.
A different target, still an unproven treatment
ATX-011 is an antibody designed to bind G6B, a protein found on platelets and the cells that produce them. Alethio says the target is also present on disease-initiating stem cells in myeloproliferative neoplasms, the group of blood cancers that includes essential thrombocythemia.
The company’s aim is to reduce platelet counts and act on cells involved in the disease. Whether that translates into a safe, lasting benefit for patients remains to be tested. Preclinical findings are not evidence that a drug prevents clots, changes the course of a cancer or works better than existing treatments in people.
Alethio said preclinical data for ATX-011 had been selected for an oral presentation at the American Society of Hematology’s 2026 annual meeting. A conference presentation is a research milestone, not a drug approval.
Oxford research attracts new backing
The company was founded as a University of Oxford spinout by professors Adam Mead and Beth Psaila. As part of the financing, Sofinnova’s Graziano Seghezzi and RA Capital’s Maxwell DeNies joined its board.
The financing gives Alethio money to test its approach. It does not settle the questions that matter to patients and their doctors: safety, benefit, who might qualify, and how long development will take. The release does not announce an approved product, a patient price or insurance coverage.
JBizNews Desk | Oxford
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
